Arecor Therapeutics - Director/PDMR Dealing

Arecor Therapeutics

21/05/2025 07:00

RNS Number : 4864J

Arecor Therapeutics PLC

21 May 2025

 

Arecor Therapeutics plc

 

("Arecor", the "Company" or the "Group")

 

Director/PDMR Dealing

 

Cambridge, UK, 21 May 2025. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that Andrew Richards (Chair), Sarah Howell (Chief Executive Officer) and Jan Jezek (Chief Scientific Officer) have all purchased ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares"). Details are included in the table below.

 

Name
Number of Ordinary Shares purchased
Price (£)
Total beneficial interest (Ordinary Shares)
Total beneficial interest (%)
Andrew Richards
31,750
0.4697
318,361
0.84%
Sarah Howell
21,077
0.4697
905,481
2.40%
Jan Jezek
10,000
0.4700
417,808
1.11%

 

 

-ENDS-

 

For more information, please contact:

 

Arecor Therapeutics plc
www.arecor.com
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
David Ellam, Chief Financial Officer
Tel: +44 (0) 1223 426060
Email:info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Broker)
Phil Davies, Sam Butcher
Tel: +44 (0) 20 7496 3000
ICR Healthcare
Chris Gardner, David Daley, Lindsey Neville
Tel: +44 (0) 20 3709 5700
Email:arecor@icrhealthcare.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.  For further details please see our website, www.arecor.com

 

 

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Andrew Richards
2
Reason for the notification
a)
Position/status
Chair
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Arecor Therapeutics plc
b)
LEI
98450093D1213A8DDD58
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares
b)
Identification Code
GB00BMWLM973
c)
Nature of the transaction
Purchase of Ordinary Shares
d)
Price(s) and volume(s)
£0.4697and 31,750Ordinary Shares
e)
Aggregated information
- Aggregated volume
- Aggregated price
N/A
f)
Date of the transaction
19 May 2025
g)
Place of the transaction
London Stock Exchange, AIM

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Sarah Howell
2
Reason for the notification
a)
Position/status
Chief Executive Officer
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Arecor Therapeutics plc
b)
LEI
98450093D1213A8DDD58
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares
b)
Identification Code
GB00BMWLM973
c)
Nature of the transaction
Purchase of Ordinary Shares
d)
Price(s) and volume(s)
£0.4697and 21,077Ordinary Shares
e)
Aggregated information
- Aggregated volume
- Aggregated price
N/A
f)
Date of the transaction
19 May 2025
g)
Place of the transaction
London Stock Exchange, AIM

 

1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Jan Jezek
2
Reason for the notification
a)
Position/status
Chief Scientific Officer
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Arecor Therapeutics plc
b)
LEI
98450093D1213A8DDD58
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares
b)
Identification Code
GB00BMWLM973
c)
Nature of the transaction
Purchase of Ordinary Shares
d)
Price(s) and volume(s)
£0.4700and 10,000Ordinary Shares
e)
Aggregated information
- Aggregated volume
- Aggregated price
N/A
f)
Date of the transaction
20 May 2025
g)
Place of the transaction
London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHAMMRTMTBTBJA